Trial · NCT07206563
Penfluridol for Relapsed/Refractory Small Cell Cancers
NCT07206563, Phase 1, Phase 2, Not yet recruiting, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Penfluridol for Relapsed/Refractory Small Cell Cancers. Trials, record NCT07206563. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07206563
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Penfluridol for Relapsed/Refractory Small Cell Cancers
- NCT number
- NCT07206563
- Status
- Not yet recruiting
- Phases
- Phase 1, Phase 2
- Enrollment
- 33 participants, estimated
- Lead sponsor
- Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
- Conditions
- Small Cell Carcinoma, Small Cell Carcinoma of Lung, Small Cell Lung Cancer ( SCLC ), Small Cell Cervical Carcinoma
- Interventions
- Penfluridol Monotherapy for Relapsed/Refractory Small-Cell Lung or Cervical Cancer
- First posted
- 2025-10-03
- Last updated
- 2025-10-03
Source ClinicalTrials.gov
Registered outcomes7
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Recommended Phase II Dose (RP2D) of penfluridol [Phase Ib] | From the first dose until the completion of the DLT observation period (21 days) for the first cohort of patients at each dose level (The Phase Ib dose-escalation stage is anticipated to take approximately 9 months). | To determine the Recommended Phase II Dose (RP2D) of oral penfluridol for the treatment of relapsed/refractory small cell lung cancer and small cell cervical cancer. |
| Primary | Objective Response Rate (ORR) [Phase II] | From the first dose of study drug until disease progression, start of new anticancer therapy, or death from any cause (whichever occurs first), assessed up to approximately 24 months. | To evaluate the antitumor activity of oral penfluridol at the RP2D as measured by the Objective Response Rate. |
| Secondary | Incidence of Treatment-Emergent Adverse Events (TEAEs) | From the first dose of study drug until 30 days after the last dose, assessed up to approximately 24 months. | To evaluate the safety and tolerability profile of oral penfluridol. |
| Secondary | Duration of Response (DOR) | From the first documented objective response until disease progression or death (whichever occurs first), assessed up to approximately 24 months. | To assess the durability of tumor responses. |
| Secondary | Progression-Free Survival (PFS) | From the first dose until disease progression or death (whichever occurs first), assessed up to approximately 24 months. | To assess disease control. |
| Secondary | Overall Survival (OS) | From the first dose until death from any cause, assessed up to approximately 36 months. | To evaluate the overall survival benefit. |
| Secondary | Disease Control Rate (DCR) | From the first dose until documented disease progression, assessed up to approximately 24 months. | To evaluate the proportion of patients achieving disease control. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07206563
GET https://conductscience.org/api/trials/v1/NCT07206563/registered